<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283695</url>
  </required_header>
  <id_info>
    <org_study_id>Mab_GX_I7</org_study_id>
    <nct_id>NCT04283695</nct_id>
  </id_info>
  <brief_title>To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-labeled, Single-dose, One-sequence, One-period, 3-part Study to Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate
      the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7
      in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate
      the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7
      in healthy volunteers To show ABA and Mass balance of GX-I7
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity at feces,urine,blood to measure total recovery rate</measure>
    <time_frame>29 days</time_frame>
    <description>radioactivity in nCi</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Leukopenia</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV: [14C]-GX-I7 40 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-I7 or [14C] GX-I7</intervention_name>
    <description>IM GX-I7 or IV/IM microdose of GX-I7</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is willing and able to give informed consent after listening character of the
             clinical trial

          2. Must be 19-45 years of age, inclusive

          3. Weight 50-100kg, BMI 18-30kg/m2

          4. Subject who is adequately able to attend the study based on medical history and
             physical exam, no clinically significant abnormality from vital sign and clinical
             laboratory values

          5. No clinical abnormality from ECG test

          6. Non-smoker (no smoking or no use of any product containing nicotine least for one
             month and negative from urine test)

        Exclusion Criteria:

          1. Suspected or confirmed malignancy, or has malignancy history

          2. Any clinically significant acute or chronic medical condition requiring care of a
             physician, in liver, biliary tract, renal, nervous system (CNS or peripheral).
             respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular
             (congestive heart failure, coronary artery disease, myocardial infarction etc),
             hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder,
             immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases

          3. Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab

          4. Are considering or scheduled to undergo any surgical or dental procedure during the
             study

          5. Administered other Investigational Product (IP) by attending other clinical study or
             biological equivalent study within recent 6 months

          6. Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical
             history with serious allergic diseases

          7. Positive from urine drug screen or respiratory alcohol screen at medical screening

          8. History of alcohol, drug, or substance abuse in the past 12 months

          9. A heavy alchol consumer (&gt;21 units/week, 1 unit = 10 g of pure alcohol) or Consumption
             of alcohol within 48 hours prior to hospitalization

         10. Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except
             maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or
             other hormone substitute within 14 days before administration

         11. Planning pregnancy or donation of sperm/disagreeing proper contraception during the
             study and 3 months following IP administration

         12. Do not have veins suitable for cannulation or multiple venipunctures

         13. Previously donate whole blood within 60 days or component blood within 14 days

         14. Excessive consumption of foods containing grapefruits

         15. Any other factor that the Investigator thinks will increase subject risk with
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Howard Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

